Document is current
Any future updates will be listed below
-
Authors
Santos-Pardo, Irene
Witt, Nils
Angerås, Oskar
Nyström, Thomas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02621489 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of exenatide on coronary stent’s endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study
https://doi.org/10.1186/s12933-023-02071-4
-
Funding
Funding for this research was provided by:
Abbott Vascular
AstraZeneca Mölndal
Novo Nordisk
Karolinska Institute
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 21 November 2023
First Online: 8 December 2023
Declarations
:
: All subjects gave their written consent to participate in the trial. The study was approved by the Ethical Review Board of the Stockholm County Regional Council, the Medical Products Agency and the Swedish Radiation Safety Authority and complies with the current ICH E6 (R2), good clinical practice guidelines and the Helsinki declaration.
: Not applicable.
: TN has received unrestricted grants from AstraZeneca and NovoNordisk and has served on national advisory boards of Amgen, Abbot, Novo Nordisk, Sanofi-Aventis, Eli Lilly, MSD and Boehringer Ingelheim. OA has received a research grant and a personal lecture fee from Abbott Vascular. ISP and NW declare that they have no competing interests.
